Candida auris

Over 3,500 clinical cases of Candida auris, a drug-resistant fungus causing severe illness, have been reported as of August 1. Experts express concern because the yeast resists multiple antifungal drugs and is often seen in healthcare facilities among vulnerable patients. The CDC reports that while case numbers fluctuated compared to last year, the organism remains an emerging threat.

Candida auris, a drug-resistant fungus, has been reported in over half of the states, with 28 states reporting more than 3,500 cases as of Aug. 1. The yeast poses an urgent threat because it resists multiple antifungal drugs and spreads easily among people undergoing complex medical care. Risk factors include severe underlying medical conditions, and symptoms can vary but may involve fever or chills.

A drug-resistant fungus called Candida auris, referred to as a 'superbug,' is spreading across the US, including New Jersey. The Centers for Disease Control reports over 3,000 cases in 23 states this year.

The drug-resistant fungus Candida auris is spreading in 23 U.S. states despite containment efforts, according to new CDC data. The deadly pathogen remains hard to eliminate in 2026.

The drug-resistant fungus Candida auris is spreading in 23 states despite containment efforts in 2026, according to new data from the Centers for Disease Control and Prevention.

Drug-resistant fungal infections are increasing in the U.S., with Candida auris being a significant concern. Oliver Kurzai, director of the National Reference Center for Invasive Fungus Infections, is associated with research on this yeast at Würzburg University in Germany.